ライフサイエンスコーパス: pneumococcal

1 common among patients with MRSA (20.0%) than pneumococcal (2.6%) and all-cause non-S. aureus (3.7%) C

2 We compared infant pneumococcal acquisition by maternal HIV status and hous

3 We studied infant pneumococcal acquisition by maternal HIV status, serotyp

4 The arsenal of pneumococcal adhesins interacts with a multitude of extr

5 Pneumococcal adhesion and infection of A549, BEAS-2B, an

6 of welding fumes to increase PAFR-dependent pneumococcal adhesion and infection of lower airway cell

7 teel welding fumes (MS-WF) on PAFR-dependent pneumococcal adhesion and infection to human airway cell

8 ection to human airway cells in vitro and on pneumococcal airway infection in a mouse model.

9 sed pneumonia, and substantial reductions of pneumococcal and hypoxic pneumonia in young children.

10 Pneumococcal and influenza vaccinations prevented furthe

11 Both pneumococcal and non-pneumococcal OM episodes, enriched

12 opment of life-saving childhood vaccines for pneumococcal and rotavirus infections while greatly expa

13 nt Swedish blood donors never immunized with pneumococcal antigens.

14 ion provides a robust strategy for combating pneumococcal antimicrobial resistance.

15 gB) or the adhesin component (RrgA) impaired pneumococcal association to human epithelial cells.

16 We tested blood by PCR for the pneumococcal autolysin gene in children aged 1-59 months

17 ructural basis for ligand restriction by the pneumococcal autolysin, revealing for the first time an

18 The incidence of non-pneumococcal bacteraemia varied little over time.

19 ke up DNA from their environment might allow pneumococcal bacteria to colonize the human nose and thr

20 are likely to play a more important role in pneumococcal biology and evolution than previously recog

21 on of MRSA CAP overlapped substantially with pneumococcal CAP, highlighting the challenge of accurate

22 Over 90 serologically distinct pneumococcal capsular polysaccharides (serotypes) are re

23 anism, which accounts for 96 of the 98 known pneumococcal capsule types, are in a chromosomal region

24 chemical modification found frequently among pneumococcal capsules is O-acetylation.

25 ent pneumococcal conjugate vaccine (PCV7) on pneumococcal carriage and the bacterial component of the

26 Based on 1,352 PspA sequences derived from a pneumococcal carriage cohort, this OMV-based vaccine for

27 However, pneumococcal carriage remained comparable due to an expa

28 te PhpP specific activity thereby regulating pneumococcal cell division.

29 eonine kinase StkP, the central regulator of pneumococcal cell division.

30 n as a pleiotropic RNA chaperone controlling pneumococcal cell division.

31 l division arrest is programmed in competent pneumococcal cells to ensure that transformation is comp

32 es with EzrA, StkP, PBP2a, PBP2b and MreC in pneumococcal cells.

33 mRNA expression and increased BALF and lung pneumococcal CFU values.

34 We find that pneumococcal challenge in Cmah(-/-) mice leads to height

35 but they failed to increase production after pneumococcal challenge, in keeping with reduced intracel

36 hosphocholine, and survival after intranasal pneumococcal challenge.

37 use mortality was monitored after intranasal pneumococcal challenge.

38 uced caspase-dependent mROS production after pneumococcal challenge.

39 Splenic mature neutrophils mediated pneumococcal clearance in the spleen by plucking bacteri

40 l type that is known to play a major role in pneumococcal clearance.

41 ther the prevalence nor the density of nasal pneumococcal colonization (by culture and qPCR) can be u

42 Pneumococcal colonization density >6.9 log10 copies/mL w

43 Among the 4035 non-MCPP cases, 500 (12%) had pneumococcal colonization density >6.9 log10 copies/mL;

44 uggested an association between upper airway pneumococcal colonization density and pneumococcal pneum

45 ecific antibody concentration and homologous pneumococcal colonization for only 1 protein.

46 y relevant animal models investigating nasal pneumococcal colonization in the context of cigarette sm

47 tions between immunoglobulins and ABTs clear pneumococcal colonization or that acquired immunity to p

48 Smoking cessation during nasal pneumococcal colonization rescued nasal neutrophil recru

49 By qPCR, pneumococcal colonization was detected in 10 LRTI patien

50 relevant cutoff of >8,000 copies/ml on qPCR, pneumococcal colonization was found in 3 LRTI patients a

51 nt mouse model that can be utilized to study pneumococcal colonization, shedding, and transmission du

52 y associated with a substantial reduction of pneumococcal colonization.

53 -recruiting chemokines, normally elicited by pneumococcal colonization.

54 tial to induce broad protection and restrict pneumococcal colonization.

55 These findings support theoretical models of pneumococcal competition and antibiotic resistance.

56 dle-income countries to study the benefit of pneumococcal conjugate vaccine (PCV) in protecting again

57 Pneumococcal conjugate vaccine (PCV) was introduced into

58 ults (CAPiTA), the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) against first epi

59 Five sites use 13-valent pneumococcal conjugate vaccine (PCV13) alone and four us

60 In 2010, the 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7.

61 dual serotypes, one or both isolates were a pneumococcal conjugate vaccine (PCV13) serotype.

62 The 13-valent pneumococcal conjugate vaccine (PCV13) was designed to i

63 .9% (12/43) (P = 0.004), after the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced.

64 (UAD) assay for 13 serotypes included in the pneumococcal conjugate vaccine (PCV13) was recently repo

65 In 2012/2013, a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) was recommended f

66 Australia introduced universal 7-valent pneumococcal conjugate vaccine (PCV7) from 2005, replace

67 Introduction of the heptavalent pneumococcal conjugate vaccine (PCV7) in 2000 reduced ma

68 Infants in the UK were first offered a pneumococcal conjugate vaccine (PCV7) in 2006, given at

69 characterised the impact of the seven-valent pneumococcal conjugate vaccine (PCV7) on pneumococcal ca

70 Pneumococcal conjugate vaccine 10 (PCV10) and pneumococc

71 neumococcal conjugate vaccine 10 (PCV10) and pneumococcal conjugate vaccine 13 (PCV13), are used in c

72 upport recommendations for widespread use of pneumococcal conjugate vaccine in low-income and middle-

73 wi, in 2009-2011, before the introduction of pneumococcal conjugate vaccine.

74 The full extent to which childhood pneumococcal conjugate vaccines (PCV) can indirectly red

75 The 7-valent and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respect

76 Pneumococcal conjugate vaccines (PCVs) are being used wo

77 Pneumococcal conjugate vaccines (PCVs) are highly effect

78 Pneumococcal conjugate vaccines (PCVs) are used in many

79 hildhood death, even though highly effective pneumococcal conjugate vaccines (PCVs) are used in natio

80 titis media (OM) burden following rollout of pneumococcal conjugate vaccines (PCVs) have exceeded pre

81 Pneumococcal conjugate vaccines (PCVs) have substantiall

82 neumonia associated with the introduction of pneumococcal conjugate vaccines (PCVs) in five countries

83 Pneumococcal conjugate vaccines (PCVs) target only a few

84 Pneumococcal conjugate vaccines are important tools in t

85 Pneumococcal conjugated vaccines (PCVs) impact on comple

86 The specific role of its pneumococcal counterpart, NanA, in this interaction, how

87 b vaccine; age 6/10/ 14 weeks) and 13-valent pneumococcal CRM197-conjugate vaccine (PCV13; age 6/14 w

88 ategies will be required to reduce childhood pneumococcal deaths in countries with established pneumo

89 against antibiotic non-susceptible invasive pneumococcal disease (65.6%, 44.9 to 78.7).

90 vaccine (PCV) in protecting against invasive pneumococcal disease (IPD) calls for alternate strategie

91 are highly effective in preventing invasive pneumococcal disease (IPD) caused by vaccine serotypes.

92 We used national surveillance of invasive pneumococcal disease (IPD) from 2002 for baseline and ap

93 We obtained ZIP code-level data on invasive pneumococcal disease (IPD) from an active population-bas

94 rect comparisons of impacts against invasive pneumococcal disease (IPD) in equivalent populations hav

95 e 1 is one of the leading causes of invasive pneumococcal disease (IPD) in West Africa, with ST618 be

96 Invasive pneumococcal disease (IPD) is usually caused by a single

97 ese programs on the epidemiology of invasive pneumococcal disease (IPD) to determine if PCV-associate

98 are highly effective in preventing invasive pneumococcal disease (IPD), but deaths due to IPD still

99 the role of sex on the incidence of invasive pneumococcal disease (IPD).

100 in 2000 reduced macrolide-resistant invasive pneumococcal disease (MR-IPD) due to PCV7 serotypes (6B,

101 CI -12 to 79) against all-serotype invasive pneumococcal disease and 94% (44 to 100) for serotype 19

102 We compared the incidence of invasive pneumococcal disease between baseline (May 12, 2008-May

103 that cigarette smoke predisposes to invasive pneumococcal disease by suppressing inflammatory process

104 INTERPRETATION: The incidence of invasive pneumococcal disease caused by all serotypes decreased d

105 By contrast, that of invasive pneumococcal disease caused by non-PCV13 serotypes incre

106 The pooled IRR for invasive pneumococcal disease caused by non-PCV13 serotypes was 1

107 ons of lives annually by preventing invasive pneumococcal disease caused by Streptococcus pneumoniae

108 noted no changes in either group in invasive pneumococcal disease caused by the additional 11 serotyp

109 t serotypes, have caused great reductions in pneumococcal disease caused by these serotypes.

110 oral indirect effects by pooling of invasive pneumococcal disease changes by serotype and serogroup.

111 or observational studies reporting invasive pneumococcal disease changes following PCV introduction

112 Invasive pneumococcal disease continues to be a major cause of mo

113 d overall and 29 (8%) patients with invasive pneumococcal disease died.

114 an 5 years with suspected or proven invasive pneumococcal disease from 18 hospitals or institutional

115 tained from pediatric patients with invasive pneumococcal disease from 1994 to 2014 and 48 isolates f

116 ould predict the incidence serotype-specific pneumococcal disease in adults 18-39 years of age and th

117 ence the effectiveness of PCVs in preventing pneumococcal disease in adults.

118 programme reduced the incidence of invasive pneumococcal disease in children aged 2-59 months by aro

119 Cases of invasive pneumococcal disease in children aged 5 years or younger

120 two or more doses of PCV13 against invasive pneumococcal disease in children with HIV infection and

121 IRR was 0.53 (95% CI 0.43-0.65) for invasive pneumococcal disease in children younger than 5 years ca

122 gh-valency PCVs on the incidence of invasive pneumococcal disease in children younger than 5 years.

123 We compared the incidence of invasive pneumococcal disease in each of the 4 years after the in

124 Invasive pneumococcal disease incidences decreased between 2005 a

125 d postmortem specimens intent on identifying pneumococcal disease to studies of multiple specimen typ

126 ine effectiveness against all-cause invasive pneumococcal disease was 60.2% (95% CI 46.8 to 70.3).

127 ses of PCV13 against PCV13-serotype invasive pneumococcal disease was 85% (95% CI 37 to 96) among 11

128 effectiveness against PCV7-serotype invasive pneumococcal disease was 87% (95% CI 38 to 97) in childr

129 mes to attaining a 90% reduction in invasive pneumococcal disease were 8.9 years (95% credible interv

130 tive approach where we subvert virus-induced pneumococcal disease without interfering with commensal

131 Among 361 (8%) patients with culture-proven pneumococcal disease, all clinical data were known for 2

132 Vs) have substantially reduced the burden of pneumococcal disease, including the incidence of otitis

133 During invasive pneumococcal disease, S. pneumoniae can gain access to t

134 smoking is a strong risk factor for invasive pneumococcal disease, the underlying mechanisms remain u

135 tes in seven European countries for invasive pneumococcal disease.

136 ming of indirect effects of PCVs on invasive pneumococcal disease.

137 y, thus affecting the resistance to invasive pneumococcal disease.

138 e cigarette smoke-exposed mice from invasive pneumococcal disease.

139 maintain population control of vaccine-type pneumococcal disease.

140 Invasive pneumococcal diseases (IPDs) remain the leading cause of

141 thus, the question remains as to what drives pneumococcal division site selection.

142 rotein MapZ was identified and implicated in pneumococcal division site selection.

143 bodies against the two receptors, we prevent pneumococcal entry into the brain and meningitis develop

144 The UAD assay detected more pneumococcal etiologies (45.0%) than the serotype-indepe

145 ic (71 [30.2%]; P < 0.001) and increased the pneumococcal etiology from 30.2% by an additional 22.6%

146 olecular interaction between fibronectin and pneumococcal fibronectin-binding proteins (FnBPs) PavA a

147 on pattern of molecular interactions between pneumococcal FnBPs and fibronectin.

148 Strikingly, both pneumococcal FnBPs recognize similar peptides in targete

149 Individual prophages and the host pneumococcal genetic lineage were strongly associated an

150 We revealed that every pneumococcal genome contained prophage DNA.

151 ed in one of five different sites within the pneumococcal genome.

152 Nearly 500 pneumococcal genomes were investigated and RNA sequencin

153 We estimated that pneumococcal genomic variation accounted for 63% of the

154 oth pflA and pflB, their mutation attenuated pneumococcal growth, and their expression was induced on

155 ompetitive inhibition experiments with other pneumococcal hTSP-1 adhesins demonstrated that PspC and

156 Pneumonia was considered pneumococcal if either sputum Gram stain, sputum culture

157 e in eliciting pulmonary inflammation during pneumococcal infection and is required for lethal system

158 ding protein were increased (P < 0.05) after pneumococcal infection in both acutely ill and convalesc

159 ith littermate controls after intrapulmonary pneumococcal infection, suggesting that IL-22 signaling

160 sufficiency with increased susceptibility to pneumococcal infection.

161 ule is effective for preventing vaccine-type pneumococcal infections in young children not infected w

162 ow in adherence and binding studies that the pneumococcal interaction with fibronectin is a non-human

163 Herein we observed that pneumococcal invasion of the myocardium occurred soon af

164 host receptor thought to bind and facilitate pneumococcal invasiveness, did not rescue cigarette smok

165 collection, and the antigen variant in each pneumococcal isolate was determined using genomic data.

166 etrospectively included laboratory-confirmed pneumococcal isolates from ten sentinel laboratories, to

167 a national reference service for serotyping pneumococcal isolates in England and Wales.

168 Pneumococcal isolates were collected prospectively.

169 Altogether, 154 pneumococcal isolates were tested.

170 erile body fluids, reconfirmed and serotyped pneumococcal isolates, and established antimicrobial sus

171 was observed for each of the well-colonizing pneumococcal isolates, with the rate of transmission pro

172 le, highly variable, and clinically relevant pneumococcal isolates.

173 Pneumococcal load in blood was not associated with respi

174 High blood pneumococcal load was associated with alveolar consolida

175 tive, nationwide cohort of 405 patients with pneumococcal meningitis and in 329 controls matched for

176 investigated the progression and outcome of pneumococcal meningitis in Rag1(-/-) mice lacking functi

177 te recent advances in antimicrobial therapy, pneumococcal meningitis remains a life-threatening disea

178 tween multiple variants in a gene region and pneumococcal meningitis susceptibility yielded one signi

179 st signals associated with susceptibility to pneumococcal meningitis were rs139064549 on chromosome 1

180 pectively) in the progression and outcome of pneumococcal meningitis, using Kaplan-Meier survival cur

181 of brain biopsies from patients who died of pneumococcal meningitis, we observe that pneumococci col

182 nctive steroid treatment is underutilized in pneumococcal meningitis, where it has shown to decrease

183 f all patients and in 39.3% of patients with pneumococcal meningitis, with an associated decrease in

184 ironment needed to establish nonhematogenous pneumococcal meningitis.

185 IgR and PECAM-1 has the potential to prevent pneumococcal meningitis.

186 SCs were related to clones identified by the Pneumococcal Molecular Epidemiology Network (PMEN).

187 Pneumococcal mutants deficient in TacL lack LTA and show

188 GBS expressing pneumococcal NanA had increased invasion of human brain

189 However, forced expression of pneumococcal NanA in GBS removed terminal sialic acid re

190 nd through heterologous expression of active pneumococcal NanA in GBS, potential costs of maintaining

191 promoted progression of stable asymptomatic pneumococcal nasopharyngeal carriage to pneumonia and in

192 ctious disease patterns, altering density of pneumococcal nasopharyngeal carriage, reducing phagocyti

193 d <5 years diagnosed with CAAP with positive pneumococcal nasopharyngeal cultures from whom viral dia

194 Pneumococcal natural transformation contributes to genom

195 We demonstrate that pneumococcal neuraminidase A (NanA), which cleaves termi

196 The primary pneumococcal neuraminidase, NanA, which is a sialidase t

197 comparing the 3 periods were calculated for pneumococcal, nontypable Haemophilus influenzae (NTHi),

198 Both pneumococcal and non-pneumococcal OM episodes, enriched with complex cases, d

199 surveillance exists to monitor the change in pneumococcal OM incidence after the introduction of PCVs

200 types, 5 additional PCV13 serotypes, and all-pneumococcal OM, respectively; non-PCV13 serotype episod

201 Vs would be associated with reduction of non-pneumococcal OM.

202 an adhesive RrgA-containing pilus-1 mediate pneumococcal passage from the bloodstream through the BB

203 s both enzymatically and nonenzymatically to pneumococcal pathogenesis and, as such, suggest that it

204 tion of S. pneumoniae as a key first step in pneumococcal pathogenesis within the heart.

205 eptide that controls biofilm development and pneumococcal pathogenesis.

206 Load was available for 290 of 291 cases with pneumococcal PCR detected in blood and 273 of 273 contro

207 Quantitative pneumococcal PCR in blood has limited diagnostic utility

208 Discussion.: The utility of pneumococcal PCR on blood for diagnosing childhood pneum

209 Blood pneumococcal PCR positivity was higher in children from

210 respiratory or blood culture) with those of pneumococcal (per respiratory or blood culture or urine

211 We conclude that pneumococcal phase variation is a complex and multifacto

212 We show that the major adhesin of the pneumococcal pilus-1, RrgA, binds both receptors, wherea

213 compared between microbiologically confirmed pneumococcal pneumonia (MCPP) cases, cases confirmed for

214 Microbiologically confirmed pneumococcal pneumonia (MCPP) was confirmed by detection

215 among cases with microbiologically confirmed pneumococcal pneumonia (MCPP), cases without a confirmed

216 of PCV13 on a number of clinical aspects of pneumococcal pneumonia (PP) in children has not been rep

217 reaction (PCR) on blood in the diagnosis of pneumococcal pneumonia among children from 7 low- and mi

218 ds and improved survival in a mouse model of pneumococcal pneumonia and sepsis.

219 rdiac tissue from six adult NHPs with severe pneumococcal pneumonia and three uninfected control anim

220 Pneumococcal pneumonia declined from 2.9 to 1.2 cases pe

221 p to one-third of patients hospitalized with pneumococcal pneumonia experience major adverse cardiac

222 Annual pneumococcal pneumonia hospitalization rates per 100 000

223 iae is the most common bacterial etiology of pneumococcal pneumonia in adults worldwide.

224 D may become a new standard for detection of pneumococcal pneumonia in adults.

225 had poor diagnostic accuracy for diagnosing pneumococcal pneumonia in children in 9 African and Asia

226 s limited diagnostic utility for identifying pneumococcal pneumonia in individual children, but may b

227 coccal PCR on blood for diagnosing childhood pneumococcal pneumonia in the 7 low- and middle-income c

228 Hypersusceptibility of welders to pneumococcal pneumonia is in part mediated by the capaci

229 PP and could be used to improve estimates of pneumococcal pneumonia prevalence in childhood pneumonia

230 During pneumococcal pneumonia, antibacterial defense requires t

231 airway pneumococcal colonization density and pneumococcal pneumonia, but data in children are limited

232 During pneumococcal pneumonia, Miwi2-deficient mice exhibited i

233 tly reported as a useful diagnostic tool for pneumococcal pneumonia.

234 e of blood lytA quantification in diagnosing pneumococcal pneumonia.

235 Welders are at increased risk of pneumococcal pneumonia.

236 gnaling in the liver is important to control pneumococcal pneumonia.

237 promise as an adjunct therapeutic avenue for pneumococcal pneumonia.

238 e of all immunoglobulins, IgG subclasses and pneumococcal polysaccharide antibodies.

239 The pneumococcal polysaccharide antibody response was impair

240 Levels of natural antibodies to the pneumococcal polysaccharide component phosphocholine wer

241 detailed antibody responses after 23-valent pneumococcal polysaccharide vaccination (23vPPV).

242 grouped serotypes contained in the 23-valent pneumococcal polysaccharide vaccine (PPV23) decreased at

243 rs after transplantation and the response to pneumococcal polysaccharide vaccine was significantly lo

244 disease, the critical determinants enabling pneumococcal progression from this niche to cause invasi

245 Pneumococcal prophages are likely to play a more importa

246 Overall, pneumococcal prophages were highly prevalent, demonstrat

247 286 full-length/putatively full-length pneumococcal prophages were identified, of which 163 hav

248 Serum immunoglobulin G (IgG) titers to 28 pneumococcal protein antigens were measured among 242 in

249 Pneumococcal proteins involved in the resistance against

250 Characterizing the immune response to pneumococcal proteins is critical in understanding this

251 period of 11 years, by a network of European pneumococcal reference laboratories.

252 ally, compared with Neu5Gc, Neu5Ac increases pneumococcal resistance to antimicrobial reactive oxygen

253 used in silico pattern searches to define a pneumococcal secretome and analyzed the transcriptome of

254 ctive variable independently associated with pneumococcal sepsis (adjusted relative risk, 2.53 [95% c

255 Pneumococcal serotype 33A has two membrane-bound O-acety

256 Studies show that both pneumococcal serotype and host genetic background affect

257 rotective antibody levels against each PCV13 pneumococcal serotype at D301.

258 THi colonization was associated with reduced pneumococcal serotype diversity among children 2-18 mont

259 Simpson's index was used to quantify pneumococcal serotype diversity.

260 external quality assessment (EQA) scheme for pneumococcal serotype identification has been performed

261 We estimated rates of pneumococcal serotype-specific progression from carriage

262 Conjugate vaccination against seven pneumococcal serotypes (PCV7) reduced disease prevalence

263 We compared invasive and noninvasive pneumococcal serotypes according to previous publication

264 ted to determine association between carried pneumococcal serotypes and respiratory viruses during ch

265 onship between pneumonia-associated invasive pneumococcal serotypes and RSV detection during CAAP.

266 However, it is unclear whether all pneumococcal serotypes are equally prone to such interac

267 gression of vaccine-targeted and non-vaccine pneumococcal serotypes from carriage to OM before and af

268 reductions in OM caused by vaccine-targeted pneumococcal serotypes have co-occurred with reductions

269 Vaccine-targeted and non-vaccine pneumococcal serotypes showed lower rates of progression

270 d was more prevalent among children carrying pneumococcal serotypes with greater capsular thickness,

271 There are at least 98 known pneumococcal serotypes.

272 utic target as it is highly conserved across pneumococcal serotypes.

273 mary (D127) and postbooster (D301) doses for pneumococcal serotypes.

274 s found to be a major factor in the level of pneumococcal shedding and required expression of capsule

275 n serogroup 18 from culturable/nonculturable pneumococcal specimens, with no cross-reactivity with ot

276 mobilization from their splenic niche after pneumococcal stimulation to increase the effector mature

277 en survivors and fatalities but not mouse or pneumococcal strains used during infection.

278 iles of transparent and opaque variants of 3 pneumococcal strains, D39 (serotype 2), WCH43 (serotype

279 chemical immunosensor for rapid detection of pneumococcal surface protein A (PspA) peptide and SP lys

280 Individuals with low titers against group 3 pneumococcal surface protein C (PspC) variants were more

281 Hic, a PspC-like pneumococcal surface protein, possesses vitronectin and

282 , which included 109 variants of the diverse pneumococcal surface proteins A and C (PspA and PspC) an

283 gh temperatures increased release of the key pneumococcal toxin pneumolysin through increased bacteri

284 sequence type-specific fixed mutation in the pneumococcal toxin pneumolysin, which is associated with

285 , protects mice from lung injury caused by a pneumococcal toxin, pneumolysin (PLY).

286 ts differed among isolates of five different pneumococcal types.

287 -unvaccinated beneficiaries who had received pneumococcal vaccination (secondary analysis).

288 ococcal deaths in countries with established pneumococcal vaccination programs.

289 eir immune response to diphtheria toxoid and pneumococcal vaccination.

290 nt immune responses to diphtheria toxoid and pneumococcal vaccination.

291 Pneumococcal vaccine coverage of OPSI patients was low o

292 ratory syncytial virus (RSV) seasons, before pneumococcal vaccine introduction.

293 Immediate replacement of pneumococcal vaccine serotypes with non-vaccine serotype

294 could help us predict the effects of future pneumococcal vaccine use in children on disease rates in

295 The long-term immunogenicity of PCV13 in pneumococcal vaccine-naive older adults was investigated

296 is B; and Haemophilus influenzae type b) and pneumococcal vaccine.

297 GAVI's Pneumococcal vaccines Accelerated Development and Introd

298 Based on our results, revaccination with pneumococcal vaccines after transplantation should be co

299 l Microbiology underscore the limitations of pneumococcal vaccines that target the polysaccharide cap

300 We report that mutations that inactivate the pneumococcal YceG-domain protein, Spd_1346 (renamed MltG